Sysmex Europe Launches Automated Blood Testing Platform for Alzheimer’s Disease
The system uses routine blood draws to provide results in 17 minutes, offering an alternative to invasive diagnostic methods.
The system uses routine blood draws to provide results in 17 minutes, offering an alternative to invasive diagnostic methods.
The funding, allocated to the Centers for Disease Control and Prevention, aims to establish more accurate normal ranges for children’s medical results.
The companion diagnostic evaluates mismatch repair deficiency, a predictive biomarker used to identify patients who may respond to PD-1-targeted therapies.
The company introduced systems for single-cell proteomics, clinical sample processing, and spatial proteomics.
In studies using National Lung Screening Trial biospecimens, a liquid biopsy assay showed similar sensitivity to low-dose CT screening and detected cancers missed by imaging.